Basilea Pharmaceutica Ltd (LTS:0QNA)

CHF 42.75 0.05 (0.11%) Market Cap: 529.09 Mil Enterprise Value: 578.57 Mil PE Ratio: 0 PB Ratio: 31.19 GF Score: 68/100

Half Year 2024 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript
Aug 13, 2024

CHF40.75 (+6.82%)

Earnings
Full Year 2023 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript
Feb 13, 2024

CHF36.5 (+10.61%)

Earnings
Basilea Pharmaceutica AG Allschwil to Acquire the Rights to Fosmanogepix from Amplyx Pharmaceuticals Inc Call Transcript
Nov 13, 2023
Half Year 2023 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript
Aug 15, 2023

CHF47.45 (+12.34%)

Earnings
Full Year 2022 Basilea Pharmaceutica AG Earnings Call Transcript
Feb 14, 2023

CHF50.08 (+4.67%)

Earnings
Half Year 2022 Basilea Pharmaceutica AG Earnings Call Transcript
Aug 16, 2022

CHF41.43 (-5.43%)

Earnings
Basilea Pharmaceutica AG to Discuss the ERADICATE Topline Results Call Transcript
Jun 28, 2022
Basilea Pharmaceutica AG at UBS Global Healthcare Conference Transcript
May 24, 2022
Full Year 2021 Basilea Pharmaceutica AG Earnings Call Transcript
Feb 15, 2022

CHF40.93 (+2.64%)

Earnings
Half Year 2021 Basilea Pharmaceutica AG Earnings Call Transcript
Aug 17, 2021

CHF44.61 (-3.49%)

Earnings
Full Year 2020 Basilea Pharmaceutica AG Earnings Call Transcript
Feb 16, 2021

CHF58.8 (-3.66%)

Earnings
Half Year 2020 Basilea Pharmaceutica AG Earnings Call Transcript
Aug 11, 2020

CHF49 (+4.66%)

Earnings
Basilea Pharmaceutica AG at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
Full Year 2019 Basilea Pharmaceutica AG Earnings Call Transcript
Feb 18, 2020

CHF56.35 (-5.77%)

Earnings
Half Year 2019 Basilea Pharmaceutica AG Earnings Call Transcript
Aug 20, 2019

CHF39.03 (+7.89%)

Earnings
Basilea Pharmaceutica AG at UBS Global Healthcare Conference Transcript
May 21, 2019

Half Year 2019 Basilea Pharmaceutica AG Earnings Call Transcript

Aug 20, 2019 / 02:00PM GMT

Release Date Price: CHF39.03 (+7.89%)

Transcript

Operator

Ladies and gentlemen, welcome to the Basilea Pharmaceutica's Half Year Results 2019 Conference Call and Live Webcast. I'm Sandra, the ChorusCall operator. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.

David Veitch

Basilea Pharmaceutica AG - CEO

Thank you. Hello. This is David Veitch, CEO of Basilea. I would like to welcome you all to our conference call and webcast, reviewing our financial results and key achievements for the first half year 2019 and also review our upcoming milestones and financial guidance for the full year 2019. I would like to mention that this call contains forward-looking statements.

This morning, we issued a press release and financial report on the results of the first half year 2019, and these documents are available on our website at basilea.com. Joining me today on the call are Adesh Kaul, our Chief Financial Officer; and Dr. Marc Engelhardt, our Chief Medical Officer.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.